An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors

American Heart Journal

Volumn 135, Issue 4, 1998, Pages

  Adgey, A A J ^a  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; HEPTAPEPTIDE; LAMIFIBAN; PLACEBO; TIROFIBAN; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ATHERECTOMY; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FIBRINOLYTIC THERAPY; HEART MUSCLE ISCHEMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; REVIEW; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

EID: 0031959918     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(98)70297-2     Document Type: Article

References (40)

1. The EPIC Investigators Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty N Engl J Med 330 1994 956 961
2. EJ Topol RM Califf HF Weisman Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months Lancet 343 1994 881 886
3. 3 blockade with percutaneous coronary intervention JAMA 278 1997 479 484
4. AM Lincoff RM Califf KM Anderson Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization J Am Coll Cardiol 30 1997 149 156
5. J Lefkovits RJ Ivanhoe RM Califf Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction Am J Cardiol 77 1996 1045 1051
6. J Lefkovits JC Blankenship KM Anderson Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC Trial J Am Coll Cardiol 28 1996 849 855
7. J Lefkovits GL Stoner KM Anderson HF Weisman EJ Topol Can conjunctive platelet glycoprotein IIb/IIIa receptor blockade improve outcomes of coronary interventions for restenotic lesions [abstract]? Circulation 92 suppl I 1995 I607
8. RM Challapalli MJ Eisenberg K Sigmon J Lemberger Platelet glycoprotein IIb/IIIa monoclonal antibody (c7E3) reduces distal embolization during percutaneous intervention of saphenous vein grafts [abstract] Circulation 92 suppl I 1995 I607
9. DJ Moliterno RM Califf K Anderson HF Weisman EJ Topol EPIC Study Investigators Special considerations for diabetics receiving platelet IIb/IIIa antagonists during coronary interventions: results from the EPIC Trial [abstract] J Am Coll Cardiol 25 1995 155A 156A
10. DB Mark JD Talley EJ Topol Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty Circulation 94 1996 629 635
11. WB Hillegass The economics of IIb/IIIa therapy J Invas Cardiol 8 suppl B 1996 30B 33B
12. BA Van Hout L Bowman DJ Zelinger ML Simoons Costs and effects in acute coronary syndrome: the case of ReoPro in high risk PTCA patients Am Heart J 135 1998 S98 S106
13. AK Goklaney JD Murphy WB Hillegass Jr Abciximab therapy in percutaneous intervention: economic issues in the United States Am Heart J 135 1998 S90 S97
14. FV Aguirre EJ Topol JJ Ferguson Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention Circulation 91 1995 2882 2890
15. The EPILOG Investigators Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization N Engl J Med 336 1997 1689 1696
16. AM Lincoff JE Tcheng RM Califf Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization Am J Cardiol 79 1997 286 291
17. AK Rao C Pratt A Berke Thrombolysis in Myocardial Infarction (TIMI) trial—phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase J Am Coll Cardiol 11 1988 1 11
18. NS Kleiman AM Lincoff DP Miller Abciximab (c7E3) reduces death and myocardial infarction but not target vessel revascularization in diabetics undergoing percutaneous transluminal coronary angioplasty: the EPILOG experience [abstract] Eur Heart J 18 suppl 1997 13
19. AM Lincoff DB Mark RM Califf Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade during coronary intervention in the EPILOG Trial [abstract] J Am Coll Cardiol 29 1997 240A
20. ML Simoons MJ de Boer MJBM van den Brand Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina Circulation 89 1994 596 603
21. The CAPTURE Investigators Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study Lancet 349 1997 1429 1435
22. P Klootwijk S Meij R Melkert ML Simoons Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE) [abstract] J Am Coll Cardiol 29 1997 367A
23. NS Kleiman EM Ohman RM Califf Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 pilot study J Am Coll Cardiol 22 1993 381 389
24. The IMPACT-II Investigators Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II Lancet 349 1997 1422 1428
25. EM Ohman NS Kleiman G Gacioch Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction: results of a randomized, placebo-controlled, dose-ranging trial Circulation 95 1997 846 854
26. Califf RM. PURSUIT. Presented at the 70th Scientific Sessions of the American Heart Association; November 9-12, 1997, Orlando, Fla.
27. P Théroux S Kouz L Roy Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina: the Canadian Lamifiban Study Circulation 94 1996 899 905
28. JH Alexander LK Newby DJ Moliterno Relationship of outcomes to treatment with lamifiban in patients undergoing PTCA: analysis of PARAGON A [abstract] J Am Coll Cardiol 29 1997 409A
29. RA Harrington DJ Moliterno F Van de Werf Delaying and preventing ischemic events in patients with acute coronary syndromes using the platelet glycoprotein IIb/IIIa inhibitor lamifiban [abstract] J Am Coll Cardiol 29 1997 409A
30. F Van de Werf Clinical trials with glycoprotein IIb/IIIa receptor antagonists in acute coronary syndromes Thromb Haemost 78 1997 210 213
31. Van de Werf F. PARAGON. Presented at the 19th Congress of the European Society of Cardiology; August 24-28, 1997, Stockholm, Sweden.
32. Harrington RA. PARADIGM. Presented at the 69th Scientific Sessions of the American heart Association, November 10-13, 1996, New Orleans, La.
33. RESTORE Economic Study Group Analysis of hospital costs and outcomes in RESTORE [abstract] J Am Coll Cardiol 29 1997 395A
34. The RESTORE Investigators Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty Circulation 96 1997 1445 1453
35. White HD. PRISM. Presented at the 46th Annual Scientific Session of the American College of Cardiology; March 16-19, 1997, Anaheim, Calif.
36. Théroux P. PRISM-PLUS. Presented at the 46th Annual Scientific Session of the American College of Cardiology; March 16-19, 1997, Anaheim, Calif.
37. RJ. Cody Results from late breaking clinical trials sessions at ACC '97 J Am Coll Cardiol 30 1997 1 7
38. J Deckers RM Califf EJ Topol AM Lincoff JE Tcheng ML Simoons Use of abciximab (ReoPro) is not associated with an increase in the risk of stroke: overview of three randomized trials [abstract] J Am Coll Cardiol 29 1997 241A
39. LA Guzman PL Whitlow EJ Topol SG Ellis A platelet glycoprotein IIb/IIIa inhibitor (ReoPro) as an adjunctive therapy in elective stenting: initial experience with safety and efficacy [abstract] J Invas Cardiol 8 1996 46
40. RA Yaryura S Simek J Benrey ReoPro plus stenting: pushing the envelope of clinical applications for stents [abstract] J Inv Cardiol 8 1996 67